VAXCYTE, INC. Accretion (Amortization) of Discounts and Premiums, Investments
VAXCYTE, INC. (PCVX) reported Accretion (Amortization) of Discounts and Premiums, Investments of $4.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-05
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $1.18M, a 73.69% decline year-over-year.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $3.11M, a 36.66% decline year-over-year.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $2.76M, a 76.33% decline year-over-year.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $2.26M, a 62.90% decline year-over-year.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $14.43M, a 62.71% decline from fiscal 2024.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $38.70M, a 11.30% increase from fiscal 2023.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $34.77M, a 3572.12% increase from fiscal 2022.
- VAXCYTE, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was $947.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.29M 10-Q · filed 2026-08-05 | $7.06M derived: sum of 3 quarters · filed 2026-08-05 | $9.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.11M 10-Q · filed 2026-05-06 | $5.88M derived: sum of 2 quarters · filed 2026-05-06 | $8.14M derived: sum of 3 quarters · filed 2026-05-06 | $12.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.03M derived: sum of 2 quarters · filed 2026-02-24 | $9.52M derived: sum of 3 quarters · filed 2026-08-05 | $14.43M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.76M derived: sum of 2 quarters · filed 2026-08-05 | $11.67M 10-Q · filed 2025-11-04 | $23.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $9.41M 10-Q · filed 2026-08-05 | $21.08M derived: sum of 3 quarters · filed 2026-08-05 | $27.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.91M 10-Q · filed 2026-05-06 | $16.59M derived: sum of 2 quarters · filed 2026-05-06 | $22.69M derived: sum of 3 quarters · filed 2026-05-06 | $32.63M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $17.78M derived: sum of 2 quarters · filed 2026-02-24 | $27.71M derived: sum of 3 quarters · filed 2026-02-24 | $38.70M 10-K · filed 2026-02-24 |
| 2024-09-30 | $6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $16.04M derived: sum of 2 quarters · filed 2025-11-04 | $27.03M 10-Q · filed 2025-11-04 | $29.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $9.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $20.93M 10-Q · filed 2025-08-06 | $23.29M derived: sum of 3 quarters · filed 2026-02-24 | $37.87M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $10.99M 10-Q · filed 2025-05-07 | $13.36M derived: sum of 2 quarters · filed 2026-02-24 | $27.93M derived: sum of 3 quarters · filed 2026-02-24 | $39.78M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.94M derived: sum of 2 quarters · filed 2026-02-24 | $28.79M derived: sum of 3 quarters · filed 2026-02-24 | $34.77M 10-K · filed 2026-02-24 |
| 2023-09-30 | $14.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $26.42M derived: sum of 2 quarters · filed 2024-11-05 | $32.41M 10-Q · filed 2024-11-05 | $33.58M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $11.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $17.83M 10-Q · filed 2024-08-06 | $19.01M derived: sum of 3 quarters · filed 2025-02-25 | $19.25M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $5.99M 10-Q · filed 2024-05-08 | $7.17M derived: sum of 2 quarters · filed 2025-02-25 | $7.40M derived: sum of 3 quarters · filed 2025-02-25 | $7.26M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.41M derived: sum of 2 quarters · filed 2025-02-25 | $1.27M derived: sum of 3 quarters · filed 2025-02-25 | $947.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $238.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $93.00K derived: sum of 2 quarters · filed 2023-11-06 | -$228.00K 10-Q · filed 2023-11-06 | -$724.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$466.00K 10-Q · filed 2023-08-08 | -$962.00K derived: sum of 3 quarters · filed 2024-02-27 | -$1.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$321.00K 10-Q · filed 2023-05-08 | -$817.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.25M derived: sum of 3 quarters · filed 2024-02-27 | -$1.58M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$925.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.25M derived: sum of 3 quarters · filed 2024-02-27 | -$1.41M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$759.00K derived: sum of 2 quarters · filed 2022-11-07 | -$910.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$481.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$151.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |